Literature DB >> 23822632

An integrated in vitro model for simultaneous assessment of drug uptake, metabolism, and efflux.

Etienne P A Neve1, Per Artursson, Magnus Ingelman-Sundberg, Maria Karlgren.   

Abstract

The absorption, distribution, metabolism, and excretion (ADME) of drugs in vivo are to a large extent dependent on different transport and metabolism routes. Elucidation of this complex transport-metabolism interplay is a major challenge in drug development and at present no in vitro models suitable for this purpose are at hand. The aim of this study was to develop flexible, well-controlled, easy-to-use, integrated cell models, where drug transport and drug metabolism processes could be studied simultaneously. HEK293 cells stably transfected with the organic anion transporting polypeptide 1B1 (OATP1B1) were subjected to either transient transfection or adenoviral infection to introduce the genes expressing cytochrome P450 3A4 (CYP3A4), NADPH cytochrome P450 oxidoreductase (POR), cytochrome b5 (CYB5A), and multidrug resistance protein 1 (MDR1), in different combinations. Thereafter, the time and concentration-dependent transport and metabolism of two well-characterized statins, atorvastatin (acid and lactone forms) and simvastatin (acid form), were determined in the different models. The results show that CYP3A4-dependent metabolism of the more hydrophilic atorvastatin acid was dependent on OATP1B1 uptake and influenced by MDR1 efflux. In contrast, the metabolism of the more lipophilic atorvastatin lactone was not affected by active transport, whereas the metabolism of simvastatin acid was less influenced by active transport than atorvastatin acid. Our results, together with the models being applicative for any combination of drug transporters and CYP metabolizing enzymes of choice, provide proof-of-concept for the potential of the new integrated cell models presented as valuable screening tools in drug discovery and development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23822632     DOI: 10.1021/mp400202d

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  7 in total

Review 1.  Interplay of drug metabolizing enzymes with cellular transporters.

Authors:  Michaela Böhmdorfer; Alexandra Maier-Salamon; Juliane Riha; Stefan Brenner; Martina Höferl; Walter Jäger
Journal:  Wien Med Wochenschr       Date:  2014-09-10

2.  Expression of the Stem Cell Marker ABCB5 in Normal and Tumor Tissues.

Authors:  Mohamed E M Saeed; Joelle C Boulos; Kevin Machel; Nasim Andabili; Thamail Marouni; Wilfried Roth; Thomas Efferth
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

Review 3.  Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia.

Authors:  Juan Eduardo Megías-Vericat; David Martínez-Cuadrón; Antonio Solana-Altabella; José Luis Poveda; Pau Montesinos
Journal:  Pharmaceutics       Date:  2022-04-17       Impact factor: 6.525

4.  Antibacterial effects of Traditional Chinese Medicine monomers against Streptococcus pneumoniae via inhibiting pneumococcal histidine kinase (VicK).

Authors:  Shuai Zhang; Jianmin Wang; Wenchun Xu; Yusi Liu; Wei Wang; Kaifeng Wu; Zhe Wang; Xuemei Zhang
Journal:  Front Microbiol       Date:  2015-05-20       Impact factor: 5.640

5.  Systems Pharmacology Dissection of Cholesterol Regulation Reveals Determinants of Large Pharmacodynamic Variability between Cell Lines.

Authors:  Peter Blattmann; David Henriques; Michael Zimmermann; Fabian Frommelt; Uwe Sauer; Julio Saez-Rodriguez; Ruedi Aebersold
Journal:  Cell Syst       Date:  2017-12-06       Impact factor: 10.304

6.  Intracellular drug bioavailability: a new predictor of system dependent drug disposition.

Authors:  André Mateus; Andrea Treyer; Christine Wegler; Maria Karlgren; Pär Matsson; Per Artursson
Journal:  Sci Rep       Date:  2017-02-22       Impact factor: 4.379

7.  Computational modeling to predict the functions and impact of drug transporters.

Authors:  Pär Matsson; Christel A S Bergström
Journal:  In Silico Pharmacol       Date:  2015-09-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.